In a groundbreaking study that reshapes our understanding of autoimmune pathogenesis, researchers have uncovered a critical interaction between immune cells and tissue-resident fibroblasts that exacerbates primary Sjögren disease (pSjD), a chronic autoimmune disorder characterized by inflammation of exocrine glands leading to dryness of the mouth and eyes among other systemic complications. This innovative research, conducted by a team at Tokushima University in Japan, reveals that the crosstalk between CD4+ T cells expressing CD153 and CD30+ fibroblasts plays a pivotal role in driving the persistent inflammation and tissue damage hallmarking Sjögren syndrome.
Autoimmune diseases have long been understood primarily through the lens of dysregulated immune cells; however, this study highlights the previously underappreciated role of fibroblasts—cells traditionally known for their structural and reparative functions in tissue architecture. The investigators employed advanced single-cell RNA and T cell receptor sequencing technologies on salivary gland tissues from a mouse model of pSjD to dissect the cellular interactions that underpin disease progression. Their analyses revealed that CD153+ CD4+ T cells engage directly with CD30+ fibroblasts, inducing the latter to expand and produce chemokines that recruit additional immune cells, thus fostering a self-sustaining inflammatory cycle.
This pathological communication between T cells and fibroblasts contributes to the formation of tertiary lymphoid structures (TLS)-like tissue aggregates within affected organs, which are reminiscent of lymph nodes but arise ectopically in chronic inflammatory environments. The TLS-like structures facilitate ongoing immune cell activation and infiltration, perpetuating tissue damage and chronic inflammation. By identifying this CD153-CD30 axis as a key driver of the autoimmune milieu in Sjögren disease, the study opens compelling avenues for therapeutic intervention targeting cellular interactions beyond the immune system itself.
Importantly, removal of CD153 expression on CD4+ T cells or neutralization of fibroblast-produced chemokines in the mouse model significantly dampened immune cell infiltration and ameliorated autoimmune pathology. These findings suggest that targeting the specific molecular signals involved in T cell-fibroblast crosstalk may effectively disrupt the pathogenic feedback loop sustaining tissue inflammation, offering a novel strategy to halt or slow disease progression.
The study’s translational relevance is further underscored by the identification of a correlating increase in CD153+ CD4+ T cells and CD30+ fibroblasts in human patients with pSjD. This positive correlation with disease severity bolsters the potential for these cell populations and their interactions to serve as biomarkers for diagnosis and monitoring, as well as potentially as targets for therapeutic development.
Such paradigm-shifting insights extend beyond Sjögren disease, with broad implications for other autoimmune and chronic inflammatory conditions where fibroblasts contribute to a diseased microenvironment. Conditions including rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease may share similar underlying mechanisms where pathogenic immune-fibroblast interactions exacerbate chronic inflammation and tissue fibrosis.
This study represents a significant advance by integrating state-of-the-art immunological and genetic techniques to decode the complex cellular dialogues that fuel autoimmunity. It compels a reevaluation of current therapeutic approaches, which predominantly focus on immune suppression, by incorporating strategies that target pathological stromal cell activity and cellular crosstalk within affected tissues.
The findings underscore the importance of comprehensive tissue microenvironment analysis in autoimmune research, highlighting that both immune cells and the stromal compartment must be considered in developing effective treatments. By targeting the CD153-CD30 axis, new drugs may prevent the formation of pathological tissue niches, thus preserving organ function and improving patient outcomes in a disease with limited curative options.
Further research building on this discovery will likely explore the molecular signaling pathways downstream of the CD153-CD30 interaction, aiming to uncover specific mediators amenable to pharmacologic inhibition. Understanding how fibroblast activation integrates with immune signaling cascades will be key to designing interventions that simultaneously modulate multiple axes of autoimmunity.
Beyond the molecular mechanisms, the study contributes crucial in vivo evidence from well-characterized animal models and corroborates these findings with human clinical data, enhancing confidence in the relevance and applicability of the results to patient care. This dual approach exemplifies the power of translational research bridging bench science and clinical medicine.
Collectively, the insights from this research provide a compelling rationale for rethinking autoimmunity as not solely an immune cell disorder but as a complex tissue disease involving dynamic interactions between immune and stromal cells. This conceptual shift holds promise for the future of personalized medicine in autoimmune diseases, potentially leading to treatments that specifically disrupt deleterious cell-to-cell communications driving chronic inflammation.
The study was led by Professor Koji Yasutomo and Dr. Kunihiro Otsuka of Tokushima University, supported by grants from Japanese scientific foundations and agencies. Published in the prestigious journal Nature Communications, this work stands out for its innovative methodology, clinical relevance, and potential to inspire novel therapeutic paradigms for a range of debilitating autoimmune conditions.
Subject of Research: Animals
Article Title: A CD4+ T cell-fibroblast crosstalk exacerbates autoimmunity in a mouse model of primary Sjögren disease
News Publication Date: 12-May-2026
References: DOI: 10.1038/s41467-026-72975-8
Image Credits: Professor Koji Yasutomo from Tokushima University, Japan
Keywords: Autoimmune disorders, Sjögren syndrome, CD4+ T cells, fibroblasts, immunology, chronic inflammation, tertiary lymphoid structures, CD153, CD30, autoimmune pathology, therapeutic targets, immune cell-fibroblast interactions
